Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 26, 2017
Pharmacy Choice - News - Generic Drugs - March 26, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 198     Next >>     Go To Page:

3/17/17 - 5 Biotech Companies Set for Major Breakouts in 2017
There's nothing more potentially rewarding right now than a visionary biotech company, poised for explosive gains, on the basis of a ground-breaking drug, medical device or procedure. Biotechs worth a look in the markets, include: Cara Therapeutics, Inc., Clovis Oncology, Inc., Biogen Inc., Celgene Corporation, Mylan N.V. amongst others. Amgen is t
3/17/17 - 5 Biotech Companies To Watch In 2017
There "s nothing more potentially rewarding right now than a visionary biotech company poised for explosive gains on the basis of a ground-breaking drug, medical device or procedure. Large-cap or small-cap, this is the definitive year of biotech, and these five picks are all set for big things in 2017- with momentous catalysts that promise massive
3/17/17 - American-made biosimilars a differentiator in US market, Coherus [Sudan Tribune]
US patients and physicians favour domestically-made biosimilars according to Coherus Biosciences. Take AbbVies Humira, for example: over 30 companies are developing a biosimilar version of it, chasing a market worth over $16 bn annually, $10.4 bn of which comes from the US. But in a results earning call this week, Coherus Biosciences CEO Denny Lanf
3/17/17 - BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
By a News Reporter-Staff News Editor at Drug Week The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen's Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis and included in all international recommendations and...
3/17/17 - Breckenridge Pharmaceutical, Inc. Announces Launch of Desvenlafaxine XR Tablets generic for Pristiq
By a News Reporter-Staff News Editor at Drug Week- Breckenridge Pharmaceutical, Inc. announced the launch of desvenlafaxine succinate extended-release tablets 50 mg and 100 mg, a generic version of Pristiq by Pfizer Inc. The ANDA was filed as a Paragraph IV on the first-to-file date and will share 180- day exclusivity with other ANDA first fil
3/17/17 - Generic Drugs to Slow Growth of Antifungal Market [Daily News Egypt]
-New proprietary research by BCC Research predicts that new and innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs. "BCC Research predicts that region and North America to account for 24.9% and 36.9
3/17/17 - Global Inhalation and Nasal Spray Generic Drugs Market by Indications, Therapeutic Classes and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc.
Inhalation and Nasal Spray Generic Drugs Market by Indication Type (Allergic Rhinitis, Asthma, COPD), Therapeutic Drug Classes (Antihistamines, Bronchodilators Albuterol, Epinephrine; Combination Drugs Azelastine (Benzalkonium Chloride), Formoterol (Budesonide), Salmeterol (Fluticasone); Corticosteroids Beclomethasone, Budesonide, Fluni
3/17/17 - How These Generic Drugs Stocks are Faring? Neurocrine Biosciences, Lannett, Rigel Pharma, and Catalent
Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Drugs- Generic equities this morning: Neurocrine Biosciences Inc., Lannett Company Inc., Rigel Pharmaceuticals Inc., and Catalent Inc.. San Diego, California headquartered Neurocrine Biosciences Inc.' s stock finished Thursday's session 4.42% lower at..
3/17/17 - Upsher-Smith Enters Agreement To Expand Marketing And Distribution Of Generic Products For U.S. Market
Upsher-Smith Laboratories, Inc. today announced that it has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute three generic products. "We are pleased to have entered into a partnership that will help Upsher-Smith build on its already strong presence in the U.S. generic marketplace," said Rusty F
3/16/17 - Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for Reasons of Safety or...
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of th
3/16/17 - Glenmark Pharmaceuticals and Evestra, Inc. Announce Partnership Agreement for Generic NuvaRing
By a News Reporter-Staff News Editor at Women's Health Weekly- Glenmark Pharmaceuticals Inc., USA, and Evestra, Inc. have completed a strategic development, license and commercialization agreement to develop and market a generic version of Merck's& Co.' s NuvaRing product- etonogestrel/ethinyl estradiol vaginal ring- designed to allow women ac
3/16/17 - Intellipharmaceutics Announces TSX Trading Symbol Change to IPCI
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that, effective at the opening of trading on Monday, March 20, 2017, common shares of the Company will commence trading on the...
3/16/17 - Teva Announces Launch of Authorized Generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States
Teva Pharmaceutical Industries Ltd. today announced the launch of the Authorized Generic of Minastrin 24 Fe 1 1 mg/20 mcg in the U.S.. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending...
3/15/17 - Altasciences Clinical Research Companies Recognized for Leadership
Altasciences Clinical Research proudly announces that its companies, Algorithme Pharma and Vince& Associates Clinical Research, have each been awarded multiple 2017 CRO Leadership Awards. This is the fourth consecutive year that Algorithme Pharma has been recognized by the industry. This year, Algorithme Pharma excelled in the Expertise and Reliabi
3/15/17 - Analyst Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Gets Downgraded By Raymond James Financial, Inc. from Strong-Buy to Outperform
Analyst Ratings For Amphastar Pharmaceuticals (NASDAQ:AMPH) Today, Amphastar Pharmaceuticals (NASDAQ:AMPH) stock was downgraded by Raymond James Financial, Inc. from Strong-Buy to Outperform with a price target of $18.00. There are 1 hold rating, 5 buy ratings on the stock. The current consensus rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) is
3/15/17 - Concordia International Announces Fourth Quarter and Fiscal 2016 Results
-Concordia International Corp., an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced its financial and operational results for the three and twelve months ended December 31, 2016. All financial references are in U.S. dollars unless otherwise noted. Consolidated revenue of $170.4...
3/15/17 - Data on Pharmaceutical and Biomedical Analysis Discussed by Researchers at University of Oslo (Parallel artificial liquid membrane extraction as an...
Data on Pharmaceutical and Biomedical Analysis Discussed by Researchers at University of Oslo. According to news originating from Oslo, Norway, by NewsRx correspondents, research stated, "Generic Parallel Artificial Liquid Membrane Extraction methods for non-polar basic and non-polar acidic drugs from human plasma were investigated with respect to.
3/15/17 - Findings from University of Geneva Broaden Understanding of Immunoglobulins (Hydrophilic Interaction Chromatography Hyphenated with Mass...
According to news reporting originating in Geneva, Switzerland, by NewsRx journalists, research stated, "The development and approval processes of biosimilar mAbs depend on their comparability to originators. The news reporters obtained a quote from the research from the University of Geneva, "The glycosylation pattern of mAbs is considered to be a
3/15/17 - Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provided a business update. PF708 is the Pfenex product candidate that is being dev
3/15/17 - TELIGENT, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Teligent, Inc. is a specialty generic pharmaceutical company. All references to " Teligent," the "Company," "we," "us," and "our" refer to Teligent, Inc. Our mission is to become a leader in the specialty generic pharmaceutical market. Under our own label, we currently market and sell generic topical and branded generic injectable pharmaceutical pr
3/15/17 - What the FDA can do to improve competition
Scott will undoubtedly improve matters at FDA, and he will need to. One of the biggest lies the FDA has perpetuated is that all generic drugs are equivalent. I'd say this was a falsehood, except that decades of data show that the FDA is fully aware of non-bioequivalence of many allegedly generic products and has done nothing much about it.
3/14/17 - Analyst Activity Needham & Company LLC Lowers Its Price Target On Amphastar Pharmaceuticals (NASDAQ:AMPH) to
Analyst Ratings For Amphastar Pharmaceuticals (NASDAQ:AMPH) Today, Needham & Company LLC lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to per share. There are 1 hold rating, 4 buy ratings on the stock. The current consensus rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) is Buy (Score: 2.80) with a consensus target price of
3/14/17 - Analyst Activity Piper Jaffray Companies Lowers Its Price Target On Amphastar Pharmaceuticals (NASDAQ:AMPH) to
Analyst Ratings For Amphastar Pharmaceuticals (NASDAQ:AMPH) Today, Piper Jaffray Companies lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to per share. There are 1 hold rating, 4 buy ratings on the stock. The current consensus rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) is Buy (Score: 2.80) with a consensus target price o
3/14/17 - Analyst Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Gets Downgraded By Raymond James Financial, Inc. from Strong-Buy to Outperform
Analyst Ratings For Amphastar Pharmaceuticals (NASDAQ:AMPH) Today, Amphastar Pharmaceuticals (NASDAQ:AMPH) stock was downgraded by Raymond James Financial, Inc. from Strong-Buy to Outperform with a price target of $18.00. There are 1 hold rating, 5 buy ratings on the stock. The current consensus rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) is
3/14/17 - ANTARES PHARMA, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. We have a portfolio of proprietary and partnered products, including several approved commercial products and five product candidates in advanced...
Articles(s): 1 - 25 of 198     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415